Dr. Xu has served as our Chief Executive Officer since June 2020. She has been our Director since June 2020, and was re-designated as an executive Director in May 2024.

Dr. Xu has over 23 years of experience in the pharmaceutical and biotechnology industries. Dr. Xu joined Chinese Peptide in June 2003, and from June 2003 to June 2018, she was the general manager of Chinese Peptide.

Dr. Xu obtained a bachelor’s degree in clinical medicine, a master’s degree in Pathophysiology and a PhD in Biochemistry and Molecular Biology from Bethune Medical University.

Dr. Li has been a Director since January 2022. He was re-designated as an executive Director in May 2024.

Dr. Li has over 30 years of experience in the pharmaceutical and biotechnology industries. Dr. Li founded Chinese Peptide in August 2001, and has been its chairman since its establishment, responsible for its strategic management, investment and financing activities.

Dr. Li obtained a bachelor’s degree in chemistry from Wuhan University. He then obtained a PhD in Science, majoring in organic chemistry in the Chinese Institute of Chemistry.Following that, Dr.Li worked as a postdoctoral research fellow at the Lawrence Berkeley Laboratory in the USA.Dr. Li obtained an MBA degree from IMD business school of Switzerland and an EMBA degree from the Cheung Kong Graduate School of Business.

Ms. Cheng has been appointed as our executive Director since May 2024.

Ms. Li has been appointed as our executive Director since May 2024.

Ms. Li joined our Group in September 2023 as the secretary to the Board.Prior to joining our Group, Ms Li was an industry expert at Firstred Capital, which is primarily engaged in buy & build opportunities with a focus on new economy industries including industrial & technology, healthcare, and consumer sectors.

Ms. Li graduated from Southeast University in the PRC, majoring in computer science. She obtained a finance master’s degree in business administration from Cheung Kong Graduate School of Business in the PRC.

Ms. Li has enriched experience in management and quality assurance in pharmaceutical sector. Ms. Li joined Chinese Peptide in 2005, and has been the director of Chinese Peptide since 2012.She has been working at the quality assurance department of Chinese Peptide, and is currently the vice president of Chinese Peptide in area of compliance, control of R&D,manufacturing and quality system. Ms. Li has been the chairperson of our ESG committee,responsible for monitoring the implementation and progress of the Company’s ESG work.

Ms. Li graduated from Henan Radio and Television University, majoring in mechanical process technology.

Mr. Wu was designated as a non-executive Director in May 2024.

Mr. Wu obtained a master’s degree in business administration from Zhejiang University.

Dr. Yu was appointed as an independent non-executive Director in May 2024.

Dr. Yu has served as (i) a director of CR-CP Life Science Fund Management Limited since May 2021; (ii) a member of the Biotech Advisory Panel of the Stock Exchange since April 2018; (iii) a member of the board of trustees of Gordon Research Conference, a group of international scientific conferences covering biological, chemical and physical sciences and the related technologies, since July 2014; (iv) a director at Asian Fund for Cancer Research since November 2012; and (v) a member of the Technology and Innovation Sub-sector of the Election Committee of Hong Kong since October 2021.

Dr. Yu obtained a bachelor’s degree and a master’s degree in science, and a PhD in Philosophy at the University of Saskatchewan.

Dr. Zhu was appointed as an independent non-executive Director in May 2024.

Since July 2016, Dr. Zhu has been a director of Changchun Yinuoke Pharmaceutical Technology Co., Ltd.  Dr. Zhu has been a director of Jianaishi Biomedical Technology (Hangzhou) Co., Ltd. since March 2018.

Dr. Zhu obtained a bachelor’s degree in medicine from Jilin Medical College and obtained a PhD in medicine from Norman Bethune Medical University.

Mr. Xia appointed as an independent non-executive Director in May 2024.

Mr. Xia has been a partner at Beijing Hongchuang Private Equity Fund Management Co., Ltd from November 2022 to the present.

Mr. Xia obtained a bachelor’s degree in international economics and trade from Shanghai University of Finance and Economics